Potential of metastin and metastin receptor as biomarkers for urological cancers

doi:10.5410/wjcu.v2.i2.10

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4548)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-1) series.

Item

Count

PDF

303

HTML

2044

Tables (1-1)

245

Sum=2592

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

949

Download

1007

Sum=1956

Jul 24, 2013 (publication date) through Nov 28, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Urology

ISSN

2219-2816

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Clin Urol. Jul 24, 2013; 2(2): 10-14
Published online Jul 24, 2013. doi: 10.5410/wjcu.v2.i2.10

Table 1 Summary of metastin and/or metastin receptor literature in the urological cancer field

	Author (yr)	Patients (n)	The methods of the analyses (sample type)	Evidence level[14]
Renal cell carcinoma	Chen et al[11]	131	IHC (tumor tissue)	2a
Renal cell carcinoma	Shoji et al[12]	54	IHC (tumor tissue)	2a
Urothelial carcinoma	Takeda et al[6]	151	IHC (tumor tissue)	2b
Bladder cancer	Sanchez-Carbayo et al[13]	69	IHC (tumor tissue)	2a
	Nicolle et al[14]	64	IHC (tumor tissue)	2b
	Cebrian et al[15]	205	RT-PCR (tumor tissue)	2b

Level 2a: Systematic review (with homogeneity) of either retrospective cohort studies or untreated control groups in randomized controlled trials; Level 2b: Retrospective cohort study or follow-up of untreated control patients in a randomized controlled trial; or derivation of a clinical decision rule or validated on split-sample only. RT-PCR: Reverse transcriptase-polymerase chain reaction; IHC: Immunohistochemical analysis.

Citation: Shoji S, Sato H, Tomonaga T, Kim H, Soeda S, Nakano M, Uchida T, Terachi T, Takeya K. Potential of metastin and metastin receptor as biomarkers for urological cancers. World J Clin Urol 2013; 2(2): 10-14
URL: https://www.wjgnet.com/2219-2816/full/v2/i2/10.htm
DOI: https://dx.doi.org/10.5410/wjcu.v2.i2.10